Drug Trial Radar · NCT04432831
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,479
Actual
Start
Aug 5, 2020
Primary completion
Oct 11, 2023
Study completion Oct 11, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.
Conditions
- Diabetic Macular Edema
Interventions
FaricimabDrug
Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.
Sham ProcedureOther
The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
- Incidence of Ocular Adverse Events in the Fellow EyeTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
- Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
Locations
320 sites in 30 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Retinal Research Institute, LLC
Phoenix, Arizona
Arizona Retina and Vitreous Consultants
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
California Retina Consultants.
Bakersfield, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Retinal Diagnostic Center
Campbell, California
The Retina Partners
Encino, California
Eye Medical Center
Fresno, California
Retina Consultants of Orange County
Fullerton, California
Southern California Permanente Medical Group
Los Angeles, California
Northern California Retina Vitreous Associates
Mountain View, California
East Bay Retina Consultants
Oakland, California
Southern CA Desert Retina Cons
Palm Desert, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants, San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
Retinal Consultants Med Group
Sacramento, California
West Coast Retina Medical Group
San Francisco, California
Orange County Retina Med Group
Santa Ana, California
California Retina Consultants
Santa Barbara, California
California Retina Consultants - Santa Maria
Santa Maria, California
Bay Area Retina Associates
Walnut Creek, California
University of Colorado; dept of ophthalmology
Aurora, Colorado
Retina Consultants of Southern
Colorado Springs, Colorado
Colorado Retina Associates, PC
Lakewood, Colorado
Retina Group of New England
Waterford, Connecticut
Rand Eye
Deerfield Beach, Florida
Retina Group of Florida
Fort Lauderdale, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Florida Eye Associates
Melbourne, Florida
Retina Care Specialists
Palm Beach Gardens, Florida
Retina Specialty Institute
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Assoc of FL
St. Petersburg, Florida
Southern Vitreoretinal Assoc
Tallahassee, Florida
Retina Associates of Florida, LLC
Tampa, Florida
Southeast Retina Center
Augusta, Georgia
Georgia Retina PC
Marietta, Georgia
Retina Consultants of Hawaii
‘Aiea, Hawaii
Showing 40 of 320 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.